vs
STANDARD BIOTOOLS INC.（LAB）与SPRUCE POWER HOLDING CORP（SPRU）财务数据对比。点击上方公司名可切换其他公司
SPRUCE POWER HOLDING CORP的季度营收约是STANDARD BIOTOOLS INC.的1.2倍（$24.0M vs $19.6M），SPRUCE POWER HOLDING CORP净利率更高（-28.6% vs -177.4%，领先148.8%），SPRUCE POWER HOLDING CORP同比增速更快（20.4% vs -11.5%），SPRUCE POWER HOLDING CORP自由现金流更多（$-3.3M vs $-23.1M），过去两年SPRUCE POWER HOLDING CORP的营收复合增速更高（14.6% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
云杉金融是一家美国消费金融公司，专注于美国国内居民太阳能项目融资以及房屋节能改造融资领域。
LAB vs SPRU — 直观对比
营收规模更大
SPRU
是对方的1.2倍
$19.6M
营收增速更快
SPRU
高出31.8%
-11.5%
净利率更高
SPRU
高出148.8%
-177.4%
自由现金流更多
SPRU
多$19.8M
$-23.1M
两年增速更快
SPRU
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $24.0M |
| 净利润 | $-34.7M | $-6.9M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | 9.4% |
| 净利率 | -177.4% | -28.6% |
| 营收同比 | -11.5% | 20.4% |
| 净利润同比 | -28.8% | -15.8% |
| 每股收益（稀释后） | $-0.09 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSPRU
| Q4 25 | — | $24.0M | ||
| Q3 25 | $19.6M | $30.7M | ||
| Q2 25 | $21.8M | $33.2M | ||
| Q1 25 | $40.8M | $23.8M | ||
| Q4 24 | — | $20.0M | ||
| Q3 24 | $22.1M | $21.4M | ||
| Q2 24 | $22.5M | $22.5M | ||
| Q1 24 | $45.5M | $18.3M |
净利润LABSPRU
| Q4 25 | — | $-6.9M | ||
| Q3 25 | $-34.7M | $-860.0K | ||
| Q2 25 | $-33.5M | $-3.0M | ||
| Q1 25 | $-26.0M | $-15.3M | ||
| Q4 24 | — | $-5.9M | ||
| Q3 24 | $-26.9M | $-53.5M | ||
| Q2 24 | $-45.7M | $-8.6M | ||
| Q1 24 | $-32.2M | $-2.5M |
毛利率LABSPRU
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | 54.8% | ||
| Q2 24 | 46.1% | 54.9% | ||
| Q1 24 | 53.1% | 51.5% |
营业利润率LABSPRU
| Q4 25 | — | 9.4% | ||
| Q3 25 | -168.5% | 27.6% | ||
| Q2 25 | -118.1% | 26.8% | ||
| Q1 25 | -80.8% | -7.1% | ||
| Q4 24 | — | -31.4% | ||
| Q3 24 | -120.9% | -173.8% | ||
| Q2 24 | -134.5% | -14.9% | ||
| Q1 24 | -132.2% | -19.7% |
净利率LABSPRU
| Q4 25 | — | -28.6% | ||
| Q3 25 | -177.4% | -2.8% | ||
| Q2 25 | -153.7% | -8.9% | ||
| Q1 25 | -63.8% | -64.4% | ||
| Q4 24 | — | -29.7% | ||
| Q3 24 | -122.0% | -250.4% | ||
| Q2 24 | -203.3% | -38.2% | ||
| Q1 24 | -70.6% | -13.4% |
每股收益（稀释后）LABSPRU
| Q4 25 | — | $-0.38 | ||
| Q3 25 | $-0.09 | $-0.05 | ||
| Q2 25 | $-0.09 | $-0.17 | ||
| Q1 25 | $-0.07 | $-0.84 | ||
| Q4 24 | — | $-0.36 | ||
| Q3 24 | $-0.07 | $-2.88 | ||
| Q2 24 | $-0.12 | $-0.45 | ||
| Q1 24 | $-0.27 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $54.8M |
| 总债务越低越好 | — | $695.5M |
| 股东权益账面价值 | $399.7M | $121.3M |
| 总资产 | $539.6M | $837.3M |
| 负债/权益比越低杠杆越低 | — | 5.74× |
8季度趋势，按日历期对齐
现金及短期投资LABSPRU
| Q4 25 | — | $54.8M | ||
| Q3 25 | $129.4M | $53.6M | ||
| Q2 25 | $158.6M | $53.5M | ||
| Q1 25 | $150.9M | $61.9M | ||
| Q4 24 | — | $72.8M | ||
| Q3 24 | $210.6M | $113.7M | ||
| Q2 24 | $269.8M | $116.6M | ||
| Q1 24 | $287.1M | $120.6M |
总债务LABSPRU
| Q4 25 | — | $695.5M | ||
| Q3 25 | — | $705.6M | ||
| Q2 25 | — | $717.1M | ||
| Q1 25 | — | $723.8M | ||
| Q4 24 | — | $730.6M | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABSPRU
| Q4 25 | — | $121.3M | ||
| Q3 25 | $399.7M | $124.9M | ||
| Q2 25 | $424.5M | $125.0M | ||
| Q1 25 | $454.6M | $130.8M | ||
| Q4 24 | — | $143.7M | ||
| Q3 24 | $489.3M | $151.6M | ||
| Q2 24 | $510.3M | $204.6M | ||
| Q1 24 | $577.3M | $213.0M |
总资产LABSPRU
| Q4 25 | — | $837.3M | ||
| Q3 25 | $539.6M | $857.1M | ||
| Q2 25 | $557.0M | $862.6M | ||
| Q1 25 | $579.6M | $878.0M | ||
| Q4 24 | — | $898.5M | ||
| Q3 24 | $681.5M | $806.8M | ||
| Q2 24 | $708.7M | $858.4M | ||
| Q1 24 | $777.7M | $867.9M |
负债/权益比LABSPRU
| Q4 25 | — | 5.74× | ||
| Q3 25 | — | 5.65× | ||
| Q2 25 | — | 5.74× | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | 5.08× | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-3.3M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $-3.3M |
| 自由现金流率自由现金流/营收 | -118.1% | -13.7% |
| 资本支出强度资本支出/营收 | 4.5% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $-3.8M |
8季度趋势，按日历期对齐
经营现金流LABSPRU
| Q4 25 | — | $-3.3M | ||
| Q3 25 | $-22.2M | $11.2M | ||
| Q2 25 | $-20.7M | $-2.3M | ||
| Q1 25 | $-30.3M | $-9.1M | ||
| Q4 24 | — | $-13.5M | ||
| Q3 24 | $-27.9M | $-1.1M | ||
| Q2 24 | $-39.0M | $-5.1M | ||
| Q1 24 | $-62.5M | $-22.2M |
自由现金流LABSPRU
| Q4 25 | — | $-3.3M | ||
| Q3 25 | $-23.1M | $11.2M | ||
| Q2 25 | $-22.6M | $-2.4M | ||
| Q1 25 | $-35.3M | $-9.2M | ||
| Q4 24 | — | $-13.6M | ||
| Q3 24 | $-30.1M | $-1.1M | ||
| Q2 24 | $-41.0M | $-5.2M | ||
| Q1 24 | $-63.3M | $-22.3M |
自由现金流率LABSPRU
| Q4 25 | — | -13.7% | ||
| Q3 25 | -118.1% | 36.5% | ||
| Q2 25 | -103.6% | -7.3% | ||
| Q1 25 | -86.6% | -38.7% | ||
| Q4 24 | — | -68.3% | ||
| Q3 24 | -136.4% | -5.1% | ||
| Q2 24 | -182.2% | -23.1% | ||
| Q1 24 | -138.9% | -121.7% |
资本支出强度LABSPRU
| Q4 25 | — | 0.0% | ||
| Q3 25 | 4.5% | 0.1% | ||
| Q2 25 | 8.7% | 0.3% | ||
| Q1 25 | 12.4% | 0.4% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | 10.2% | 0.1% | ||
| Q2 24 | 8.6% | 0.4% | ||
| Q1 24 | 1.7% | 0.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
SPRU
暂无分部数据
